ArticleCell cycle (Georgetown, Tex.)2014
Oxidizing to death: disulfiram for cancer cell killing.
Article in Cell cycle (Georgetown, Tex.), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Redox rewiring in glioblastoma: the thioredoxin system as a precision therapeutic target.Pharmacological reports : PR · 2026Review
- The immunomodulatory function and antitumor effect of disulfiram: paving the way for novel cancer therapeutics.Discover oncology · 2023Review
- Co-delivery of a tumor microenvironment-responsive disulfiram prodrug and CuONanoscale advances · 2023Article
- Potential of Copper and Copper Compounds for Anticancer Applications.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Disulfiram Oxy-Derivatives Suppress Protein Retrotranslocation across the ER Membrane to the Cytosol and Initiate Paraptosis-like Cell Death.Membranes · 2022Article
- Article
- Near-infrared light triggered activation of pro-drug combination cancer therapy and induction of immunogenic cell death.International journal of pharmaceutics · 2021Article
- Article
- Recent Advances in Repurposing Disulfiram and Disulfiram Derivatives as Copper-Dependent Anticancer Agents.Frontiers in molecular biosciences · 2021Review
- Overview of AntabuseCancer management and research · 2021Review
- Photopolymerizable Biomaterials and Light-Based 3D Printing Strategies for Biomedical Applications.Chemical reviews · 2020Review
- Biomimetic metal-organic nanoparticles prepared with a 3D-printed microfluidic device as a novel formulation for disulfiram-based therapy against breast cancer.Applied materials today · 2020Article
- Soft and Condensed Nanoparticles and Nanoformulations for Cancer Drug Delivery and Repurpose.Advanced therapeutics · 2020Article
- Vitamin BBiomolecules · 2020Article
- The Evolving Role of Disulfiram in Radiobiology and the Treatment of Breast Cancer.OncoTargets and therapy · 2020Review
- The biological activity of bispecific trastuzumab/pertuzumab plant biosimilars may be drastically boosted by disulfiram increasing formaldehyde accumulation in cancer cells.Scientific reports · 2019Article
- Recent Advances in Antabuse (Disulfiram): The Importance of its Metal-binding Ability to its Anticancer Activity.Current medicinal chemistry · 2018Review
- BRCA1 and BRCA2 tumor suppressors protect against endogenous acetaldehyde toxicity.EMBO molecular medicine · 2017Article
- A Comparative Cytotoxic Evaluation of Disulfiram Encapsulated PLGA Nanoparticles on MCF-7 Cells.International journal of hematology-oncology and stem cell research · 2017Article
- Docosahexaenoic acid and disulfiram act in concert to kill cancer cells: a mutual enhancement of their anticancer actions.Oncotarget · 2017Article
Corrections and comments
- Comment on
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.